37 results about "Monoamine oxidase B" patented technology

The present invention provides for the identification, isolation and uses of mammalian Monoamine Oxidase C (MAO-C), also known as renalase.

The present invention provides methods of using Monoamine Oxidase C (MAO-C), also known as renalase, as a therapeutic protein in its active and inactive forms. Administering inactive renalase protein to individuals with lower renalase levels can be used to provide them with an adequate pool of the protein that can be activated by the body as needed. Active renalase protein can be administered to individuals needing an immediate reduction of catecholamine levels. An inhibitor of renalase may be used to enhance adrenergic action.

The present invention provides a group of tobacco alkaloids, tobacco extract, Yerbamaté extract, and an extract of chewing gum and lozenges which are modulators of monoamine oxidase (MAO) activity (i.e., compounds and substances which inhibit MAO enzyme and prevent its biological activity). The MAO inhibitors of the present invention can cause an increase in the level of norepinephrine, dopamine, and serotonin in the brain and other tissues, and thus can cause a wide variety of pharmacological effects mediated by their effects on these compounds. The MAO inhibitors of the present invention are useful for a variety of therapeutic applications, such as the treatment of depression, disorders of attention and focus, mood and emotional disorders, Parkinson's disease, extrapyramidal disorders, hypertension, substance abuse, smoking substitution, anti-depression therapy, eating disorders, withdrawal syndromes, and the cessation of smoking.

The invention discloses the application of fluevirosines A in preparation of a monoamine oxidase (MAO) inhibitor. Compared with an existing MAO inhibitor, the fluevirosines A has the advantages that the inhibitory activity and selectivity to MAO-A and MAO-B are improved greatly. The application of the fluevirosines A in preparation of the MAO inhibitor is disclosed for the first time. Besides, the fluevirosines A has the advantages of being high in inhibitory activity to the MAO and prominent in substantive features, and makes remarkable progress in treatment of diseases related to disorder of the MAO.

The invention provides the application of spirooliganones B in preparation of a monoamine oxidase (MAO) inhibitor. Compared with an existing MAO inhibitor, the spirooliganones B has the advantages that the inhibitory activity and the selectivity to MAO-A and MAO-B are improved greatly. The application of the spirooliganones B in preparation of the MAO inhibitor is disclosed for the first time. The spirooliganones B has the advantages of being high in inhibitory activity for the MAO and prominent in substantive features, and makes remarkable progress in treatment of diseases related to disorder of the MAO.

The invention described herein provides a fast dispersing oral solid dosage form containing monoamine oxidase B inhibitor (MAO-B inhibitor) as the active ingredient, and method of treating disease therewith, such as Parkinson's disease. In one embodiment, the monoamine oxidase B inhibitor selegiline or its analogue can be the sole active ingredient in the composition administered. The dosage form composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and / or esophageal mucous membrane tissue, such that at least 5% of the active ingredient is absorbed within one minute of placement in the oral cavity, as determined by a buccal absorption test. Monoamine oxidase B inhibitor compounds administered in accordance with the invention decrease the amount of undesirable metabolites associated with first pass effect of selegiline, for example, such as amphetamine and methamphetamine. The invention provides a number of other advantages over conventional orally administered tablet forms, including administration of monoamine oxidase B inhibitor compounds to patients that have difficulty swallowing.